id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9776 R34964 |
Coste (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Diagnosis Mental retardation (F70–F79) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
0.60 [0.10;2.90] excluded (control group) |
2/502 15/2,916 | 17 | 502 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9777 R34982 |
Coste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 | Diagnosis Mental retardation (F70–F79) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.60 [0.40;6.60] | 2/468 3,385/1,707,707 | 3,387 | 468 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9732 R34652 |
Meador (Carbamazepine), 2013 | IQ <70 (DAS) (at 4.5 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 7.04 [0.33;149.72] C | 2/54 0/73 | 2 | 54 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9712 R34570 |
Cummings (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Significant delay (score ≥2 SD below the mean) (Bayley Scales of Infant Development or the Griffiths Scale) (mean age in years: m1=3.0 and m0=2.7) | throughout pregnancy | retrospective cohort (registry) | exposed to other treatment, sick excluded | Adjustment: No |
3.71 [0.17;79.77] C excluded (control group) |
2/49 0/35 | 2 | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9713 R34573 |
Cummings (Carbamazepine) (Controls unexposed, disease free), 2011 | Significant delay (score ≥2 SD below the mean) (Bayley Scales of Infant Development or the Griffiths Scale) (mean age in years: m1=3.0 and m0=4.3) | throughout pregnancy | retrospective cohort (registry) | unexposed, disease free | Adjustment: No | 1.83 [0.16;20.91] C | 2/49 1/44 | 3 | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 2.02 [0.65;6.23] | 3,392 | 571 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, NOS) (Mixed indications; 2: Carbamazepine; 3: Carbamazepine) (Controls unexposed, disease free;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9712, 9776